Format

Send to

Choose Destination
Biomed Pharmacother. 2019 Jan;109:770-778. doi: 10.1016/j.biopha.2018.10.139. Epub 2018 Nov 5.

Molecular targeting for treatment of human T-lymphotropic virus type 1 infection.

Author information

1
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2
Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
3
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4
Immunology Research Center, Division of Inflammation and Inflammatory Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
5
School of Medical Sciences/Pharmacology, UNSW Sydney, Kensington, NSW 2052, Australia. Electronic address: r.griffith@unsw.edu.au.
6
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: mashkaniba@mums.ac.ir.

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) infection is linked to adult T-cell leukemia-lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and several other disorders. ATLL occurs in approximately 5% of the 15-20 million people infected by HTLV-1 in the world. In general, ATLL is resistant to chemotherapy, which underlines the need for new and effective therapeutic strategies. Previous studies highlighted the role of viral enzymes, responsible for viral replication, and regulatory proteins such as Tax and HBZ in the progression of HTLV-1-associated diseases. There are conflicting reports on the efficacy of current enzyme inhibitors, mainly developed against human immunodeficiency virus (HIV), for treatment of HTLV-1 infection. New treatment approaches including monoclonal antibodies show promising results and exert significant cytotoxic effects on ATLL cells. This manuscript reviews the recent developments in molecular targeting for treatment of HTLV-1 infection.

KEYWORDS:

Adult T-cell leukemia-lymphoma (ATLL); Antiviral therapy; Human T-cell lymphotropic virus 1 (HTLV-1); Integrase; Protease; Reverse transcriptase

PMID:
30551530
DOI:
10.1016/j.biopha.2018.10.139
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center